Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Surrozen, Inc.NASDAQ: SRZN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $9.33M rose 42.2% year over year, behind the +45.7% change in trailing-twelve-month research & development. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at -7.4% a year.

Context

  • Research & development amounted to 844.5% of revenue in FY2025, up 646.2 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +42.2% toward the trailing-twelve-month pace of +45.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.33M+3.7% QoQ
Last fiscal yearDec 2025
$29.37M+39.0% YoY
LTMMar 2026
$32.14M+45.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.2%——
1 year+39.0%——
3-year CAGR-7.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
29.37M USD
Year-over-year change
+39.0%
4-year CAGR
-5.5%

Research & Development vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's LTM Mar 2026 research & development of $32.14M is the 5th highest of the 8 companies compared; the peer median is $32.45M.
  • Its year-over-year change of +45.7% is the 3rd highest of 8, against a peer median of +11.2%.
  • Research & development amounts to 428.8% of revenue for SRZN, versus a peer median of 274.8%.
SRZN Competitors Peer median
Research & Development for SRZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SEERSeer, Inc.LTM Mar 2026$41.33M -11.2%-6.2%274.8%
AGENAgenus Inc.LTM Mar 2026$38.53M -58.1%—31.1%
IRDOpus Genetics, Inc.LTM Mar 2026$33.44M +11.2%+29.0%279.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M -22.6%+7.0%—
SRZNSurrozen, Inc.LTM Mar 2026$32.14M +45.7%-7.4%428.8%
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M +102.3%+57.1%—
TILInstil Bio, Inc.LTM Mar 2026$20.04M +101.3%-58.6%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$15.76M +21.0%+38.5%—
Peer median (excluding SRZN) $32.45M+11.2%+18.0%274.8%

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.5M010.66M3.48M
Cost of Revenue3.3M3.27M27.23M0537K
Gross Profit(3.3M)9.23M(27.23M)10.66M2.94M
Gross Margin—73.8%—100.0%84.6%
Research & Development36.88M37.01M27.23M21.13M29.37M
Selling, General & Admin14.21M19.83M15.8M15.06M16.2M
Operating Expenses51.09M53.57M18.55M36.19M45.03M
Depreciation & Amortization3.3M1.96M1.91M1.44M537K
EBITDA(51.35M)(34.05M)(41.13M)(62.12M)(241.49M)
EBITDA Margin—-272.4%—-583.0%-6945.3%
Operating Income(54.39M)(44.34M)(45.78M)(25.54M)(42.09M)
Operating Margin—-354.7%—-239.7%-1210.6%
Interest Income72K781K2.34M1.69M3.02M
Interest Expense00000
Other Income / Expenses(257K)8.34M2.74M(38.03M)(199.93M)
Income Before Tax(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Pre-Tax Margin—-288.0%—-596.6%-6960.8%
Income Tax Expense00000
Net Income(52.51M)(36M)(43.04M)(63.56M)(242.03M)
Net Margin—-288.0%—-596.6%-6960.8%
EPS (Basic)(23.40)(15.55)(21.33)(21.67)(32.37)
EPS (Diluted)(23.40)(15.55)(21.33)(21.67)(32.37)
Weighted Avg Shares2.34M2.31M2.02M2.93M7.48M
Weighted Avg Shares (Diluted)2.34M2.31M2.02M2.93M7.48M

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.